Daily Glow Medical Spa
- Acne Treatment
- Peptide Therapy
- Hormone Replacement Therapy (HRT)
- Stem Cell Therapy
San Diego, CA
San Diego's stem-cell market sits between UC San Diego Health, Scripps, Sanford Burnham Prebys, and Salk research gravity and a cash-pay strip that runs La Jolla and Carmel Valley medical corridors, Hillcrest and downtown suites, Mission Valley recovery shops, and North County offices that still filter under San Diego. Cross-border medical tourism adds another layer: some Directory rows are San Diego-facing brands with procedure sites in Tijuana. Same "stem cell" label can mean same-day bone marrow or adipose product, an allogeneic cord marketing pitch, or an investigational protocol. Those are not interchangeable.
This hub lists Directory clinics for San Diego and stem-cell therapy. Inclusion is not an endorsement. Listing order is not paid ranking. Regenerated.com is free for patients. Featured slots stay labeled; Verified means credential checks, not spend.
When you evaluate San Diego options, ask what tissue or cell source is used, whether the product is same-day autologous or allogeneic, who performs the procedure, what outcomes they track, how adverse events are handled, and whether marketing language matches FDA product category (Section 361 vs products that need IND or BLA pathways). California SB 1004 (2017) requires written disclosure when a provider offers non-FDA-approved stem cell therapies. Academic gravity around UCSD and Scripps does not automatically clean up private-clinic advertising in La Jolla or along the border corridor.
Prefer clinicians who can explain risks in plain language, document informed consent, and tie claims to published evidence grades rather than before/after grids. We omit invented city price averages here.
Before you trust badges or counts on this page, read How to read a Regenerated city hub and Featured vs Verified vs organic. Then return here for local listings.
Regulatory context
California cellular therapy providers are subject to 21 CFR Part 1271. Minimally manipulated human cells, tissues, and cellular and tissue-based products used for homologous use are regulated under Section 361 without premarket approval. Products that are more than minimally manipulated, used non-homologously, or combined with a drug or device are regulated as biologics under Section 351 and require an IND for clinical use or a BLA for marketing. Adipose-derived stromal vascular fraction, culture-expanded mesenchymal stem cells, and exosomes used for orthopedic, cosmetic, neurologic, and longevity indications are generally Section 351 products.
California has been a focal point of federal enforcement. In United States v California Stem Cell Treatment Center (2022), the Ninth Circuit upheld FDA authority to regulate stromal vascular fraction as a Section 351 drug, resulting in a permanent injunction against the clinic. The FDA has issued multiple warning letters to California providers marketing stem cell and exosome therapies. The Medical Board of California has disciplined physicians for false advertising under BPC 651 and for administering unapproved biologics. The California Department of Public Health enforces tissue bank licensing. Class-action consumer suits against regenerative clinics have produced settlements.
Available here
Nationwide
Stem Cell Therapy clinics across the US